Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674105 | 0.79 | P2RY12 (0.35) | L3MBTL1KMT2APOLBGAA | |
| SCHEMBL4671255 | 0.79 | P2RY12 (0.35) | L3MBTL1KMT2APOLBGAA | |
| SCHEMBL4671250 | 0.79 | P2RY12 (0.35) | L3MBTL1KMT2APOLBGAA | |
| SCHEMBL22365090 | 0.77 | P2RY12 (0.33) | CYP2C19CYP1A2CYP2C9L3MBTL1KMT2A | |
| SCHEMBL10402927 | 0.75 | CYP26A1 (0.40) | CYP26A1CYP3A4CYP2D6KMT2AALDH1A1 | |
| SCHEMBL23067830 | 0.74 | P2RY12 (0.38) | L3MBTL1 | |
| SCHEMBL23067828 | 0.74 | TBXAS1 (0.38) | CYP26A1KMT2ATBXAS1 | |
| SCHEMBL29100674 | 0.73 | HRH4 (0.49) | KMT2AALDH1A1HPGD | |
| SCHEMBL29100675 | 0.73 | HRH4 (0.49) | KMT2AALDH1A1HPGD | |
| SCHEMBL22365088 | 0.72 | P2RY12 (0.34) | L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382918-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-11-30 | — | — | US | disclosed |
| US-11384088-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2022-07-12 | — | — | US | disclosed |
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2021-04-13 | — | — | US | disclosed |
| US-20200095257-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384088-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | CYP26A1 3944/4885CYP3A4 4624/4885CYP2C19 4504/4885 |
| US-20230382918-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | SLC30A5, SLC40A1, FOLH1 | CYP26A1 3944/4885CYP3A4 4624/4885CYP2C19 4504/4885 |
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | CYP26A1 3944/4885CYP3A4 4624/4885CYP2C19 4504/4885 |
| US-20200095257-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | SLC30A5, SLC40A1, FOLH1 | CYP26A1 3944/4885CYP3A4 4624/4885CYP2C19 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.